3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Completed
2
Active not recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Head & Neck
2
Conditions
Squamous Cell Carcinoma of Head and Neck
2
Interventions
pembrolizumab
244
Nivolumab
140
Cisplatin
135
Cyclophosphamide
134
Paclitaxel
113
Carboplatin
108
Gemcitabine
98
Radiotherapy
83
Dexamethasone
83
Docetaxel
77
atezolizumab
68
Ipilimumab
68
Doxorubicin
62
Fluorouracil
60
Blood Specimen Collection
58
Bevacizumab
58
fludarabine
54
Rituximab
54
Etoposide
53
Oxaliplatin
52
Surveys and Questionnaires
49
Lenalidomide
49
Prednisone
47
Standard of Care
45
Magnetic Resonance Spectroscopy
45
Cetuximab
44
Capecitabine
44
lenvatinib
43
Radiosurgery
43
durvalumab
42
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
soluble LAG-3 protein, human
×
1 year
×
Clear all
NCT03625323
2026-04-22
TACTI-002
Immutep S.A.S.
Phase 2
Completed
187 enrolled
13 charts
NCT04811027
2025-12-11
TACTI-003
Immutep S.A.S.
Phase 2
Completed
171 enrolled